Bet on Earnings, No...
Health Care: Drugs
NewLink Genetics Corp (NLNK: NASDAQ)
$21.63 0.32 | 1.50%
06/18/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 21.31 |
| 52 Week High | 21.50 |
| 52 Week Low | 10.60 |
| Avg. Daily Vol. (Mil) | 0.19 |
| Beta (3 year) | 0.00 |
| Share Related Items | |
| Mkt Cap (Mil) | 545.64 |
| Shares Out (Mil) | 25.60 |
| Float (Mil) | 16.89 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 20.00 |
| Current Ratio | 20.90 |
| LT Debt/ Equity | 0.02 |
| Total Debt / Equity | 0.02 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 359.45 |
| Price/Book | 9.09 |
| Price/Cash Flow | -14.90 |
| Per Share Data | |
| Earnings | -1.22 |
| Sales | 0.06 |
| Book Value | 2.34 |
| Cash Flow | -1.43 |
| Business Summary | |
|---|---|
| NewLink Genetics Corp., is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. | |
| General Information | |
| 2503 South Loop Drive
Suite 5100 Ames, IA 50010 |
|
| www.linkp.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 94 | |
| CEO: Mr. Charles J. Link, Jr | |
| Short Interest | |
| Current Month (Mil) | 3.32 |
| Previous Month (Mil) | 2.86 |
| Short Interest Ratio (Days) | 13.90 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -52.40 |
| Return on Investments | -61.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with NLNK
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
Latest NLNK Headlines from TheStreet
- NewLink Genetics Corp Stock Sees Short Interest Expand By 16% 06.13.13 | 02:06 pm
- 3 Biotech Stocks Spiking With Big Volume 05.13.13 | 02:05 pm
- Most Profitable Second Quarter Biotech Stocks 04.02.13 | 06:04 am
- 5 Stocks With Big Insider Buying 02.06.13 | 12:02 pm
- Top Insider Trades: FB NLNK GD NOW 02.06.13 | 09:02 am
- Celgene CVR: Upside Into Abraxane Pancreatic Cancer Trial Data 09.25.12 | 08:09 am
- NewLink Announces An Investigator Initiated Phase 2 Study Of Sipuleucel-T Plus Indoximod In The Treatment Of Certain Men With Advanced Prostate Cancer 09.21.12 | 08:09 am
- NewLink CEO To Participate In Panel Entitled "Innovation In Immunotherapy And Vaccines" 09.20.12 | 08:09 am
- NewLink Genetics Corporation Reports Second Quarter 2012 Financial Results 08.14.12 | 08:08 am
- Pharma IPOs Are Good Medicine 07.23.12 | 07:07 am
Press Releases for NLNK
- NewLink Genetics Presents Preclinical Data On New IDO Pathway Inhibitor, NLG919, At AACR 2013 Annual Meeting - PR Newswire 04.08.13 | 07:04 am
- NewLink Genetics Presents Preclinical Data On NLG919, A New Drug Candidate From A Novel Class Of IDO Pathway Inhibitors For The Treatment Of Cancer - PR Newswire 04.04.13 | 07:04 am
- NewLink Genetics Initiates Phase 2 Trial Of IDO Pathway Inhibitor, Indoximod, For The Treatment Of Metastatic Breast Cancer - PR Newswire 04.02.13 | 07:04 am
- NewLink Genetics Announces Timing Of Fourth Quarter And Year-End 2012 Financial Results Conference Call - PR Newswire 02.25.13 | 11:02 am
- NewLink Genetics Corporation Announces Exercise Of Underwriters' Option And Closing Of Public Offering Of Common Stock - PR Newswire 02.04.13 | 09:02 am
- NewLink Genetics Corporation Announces Pricing Of Public Offering Of Common Stock - PR Newswire 01.30.13 | 09:01 am
- NewLink Genetics Corporation Announces Proposed Public Offering Of Common Stock - PR Newswire 01.29.13 | 04:01 pm
- NewLink Genetics Appoints Mr. Brian Wiley As Vice President Of Business Development - PR Newswire 01.03.13 | 07:01 am
- Clinical Data From NewLink Genetics' HyperAcute Prostate Cancer Immunotherapy Published In Journal Of Immunotherapy - PR Newswire 12.13.12 | 07:12 am
- NewLink Genetics Receives European Orphan Designation For Algenpantucel-L Immunotherapy To Treat Pancreatic Cancer - PR Newswire 11.14.12 | 07:11 am
Partner Headlines for NLNK
- A Gold Mine In Biotechnology: The Companies Poised To Benefit - Seeking Alpha 09.04.12 | 09:09 am
- NewLink Genetics DROPS 11% and 4 Stock Analyses Making Waves - Wall St. Cheat Sheet 07.18.12 | 12:07 pm
- These Are Four of the Hottest Biotechs in the Market Right Now - Benzinga 07.05.12 | 01:07 pm
- Weekly CEO Sells Highlight: Universal Insurance Holdings Inc, Avanir Pharmaceuticals Inc, Bel ... - GuruFocus 06.30.12 | 11:06 am
- Zumiez Lifted Among These Equity Analyst Insights Today - Wall St. Cheat Sheet 06.19.12 | 08:06 am
- Active Stock Alerts: Edwards Lifesciences, Pandora Media, NewLink Genetics, VMware June 6th - Wall St. Cheat Sheet 06.06.12 | 11:06 am
- New Share Price Targets to Evaluate Now - Wall St. Cheat Sheet 06.06.12 | 04:06 am
- Analysts Unveil These New Share Price Targets Tuesday - Wall St. Cheat Sheet 05.29.12 | 03:05 am
- Stock Insights: Costco Wholesale, Human Genome, NewLink Genetics, VeriFone,General Mills May 25th - Wall St. Cheat Sheet 05.25.12 | 10:05 am
- Must Know Share Price Targets That Changed Today - Wall St. Cheat Sheet 05.25.12 | 04:05 am
